Advance in new oral drugs for multiple sclerosis
Multiple sclerosis is an autoimmune inflammatory demyelinating disease of the central nervous system and represents one of the most common causes of chronic neurologic disability. Until recently, major treatments have relied on agents by injection which can induce injection ⁃related adverse events....
Main Authors: | Guan⁃en ZHOU, Zhong⁃ping AN |
---|---|
Format: | Article |
Language: | English |
Published: |
Tianjin Huanhu Hospital
2012-04-01
|
Series: | Chinese Journal of Contemporary Neurology and Neurosurgery |
Subjects: | |
Online Access: | http://www.cjcnn.org/index.php/cjcnn/article/view/140 |
Similar Items
-
Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis
by: A. N. Boyko, et al.
Published: (2019-12-01) -
Progress in the diagnosis and treatment of multiple sclerosis
by: Shi-fang HOU, et al.
Published: (2014-10-01) -
Clinical trials in relapsing-remitting multiple sclerosis (a new proposal for dealing with basic problems and restrictions)
by: Mieczyslaw Wender, et al.
Published: (2015-06-01) -
Development of a sensitive outcome for economical drug screening for progressive multiple sclerosis treatment
by: Peter Kosa, et al.
Published: (2016-08-01) -
New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability
by: Ann Marie Weideman, et al.
Published: (2017-11-01)